-

Drug Farm Doses First Patient in Phase 1 Trial for ALPK1 Inhibitor, DF-003

First-in-human trial for DF-003, the 2nd compound from IDInVivo and MedChem5 platform to enter clinical trials

GUILFORD, Conn. & SHANGHAI--(BUSINESS WIRE)--Drug Farm, a clinical-stage biopharmaceutical company, announced today that the first subject in the Phase 1 clinical trial (NCT05997641) evaluating DF-003 in healthy volunteers has been dosed. DF-003, discovered through Drug Farms’ IDInVivo and MedChem5 platform technologies, is an investigational small molecule drug that inhibits alpha-kinase 1 (ALPK1), a key target regulating inflammation pathways that underly disease pathology in cardio-renal diseases. A gain-of-function mutation in ALPK1 also causes a rare genetic disease, ROSAH syndrome, that leads to blindness.

“We are excited to see the fruits of our technology lead to the initiation of this study for the first-in-class drug, DF-003,” said Dr. Tony Xu, Ph.D., co-founder and Chief Operating Officer of Drug Farm. DF-003 is a potent, highly selective, orally bioavailable ALPK1 inhibitor with preclinical efficacy in cardio-renal and ROSAH disease animal models.

“The Phase 1 study will evaluate DF-003 in healthy volunteers with single and multiple ascending doses that will inform dose selection for the Phase 2 programs. We look forward to completing the Phase 1 study and providing a new therapeutic option for patients afflicted with heart and kidney disease, and ROSAH syndrome,” said Drug Farm’s Chief Medical Officer, Dr. Jeysen Yogaratnam, MB.BCh, MRCSEd, Ph.D., MBA.

About Drug Farm

Drug Farm is a private biotechnology Company developing innovative treatments targeting innate immunity for hepatitis B, heart and kidney diseases, and ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: www.drug-farm.com

Contacts

United States:
Henri Lichenstein, Ph.D.
Chief Executive Officer
hlichens@drug-farm.com

China:
Tony Xu, Ph.D.
Co-founder and Chief Operating Officer
tony.xu@drugfarminc.com

Industry:

Drug Farm

Release Summary
First patient dosed in Drug Farm's Phase 1 trial for ALPK1 inhibitor, DF-003.
Release Versions
English

Contacts

United States:
Henri Lichenstein, Ph.D.
Chief Executive Officer
hlichens@drug-farm.com

China:
Tony Xu, Ph.D.
Co-founder and Chief Operating Officer
tony.xu@drugfarminc.com

Social Media Profiles
Drug Farm/Linkedin
More News From Drug Farm

Drug Farm Announces FDA Acceptance of DF-003 into Rare Disease Evidence Principles Process for ROSAH Syndrome

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced that the U.S. Food and Drug Administration (U.S. Food and Drug Administration, FDA) has accepted DF-003, the company’s investigational therapy for ROSAH syndrome, into the FDA Rare Disease Evidence Principles Process (RDEP). The RDEP is an FDA initiative designed to facilitate early dialogue between the agency and sponsors developing therapies for rare diseases. Through the program, FDA works with selected sponsors to discuss r...

Drug Farm Announces FDA Fast Track Designation for First-in-Class ALPK1 Inhibitor DF-003 for the Treatment of ROSAH Syndrome

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--FDA fast tracks DF-003 for ROSAH syndrome, announces Drug Farm....

Drug Farm Announces Agreement with Cincinnati Children’s Hospital Medical Center to Explore ALPK1 Inhibitor, DF-003 as a Potential Treatment for Heart Disease and Blood Cancers Driven by Clonal Hematopoiesis

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm, Cincinnati Children’s Collaborate on DF-003 as Potential Therapy for Heart Disease and Blood Cancers...
Back to Newsroom